PSMB9 and nasopharyngeal carcinoma: Analogous immunotherapeutic approaches, often using T cells specifically targeting the Latency II antigens EBNA1, LMP1, and LMP2, have had more limited success against HL (181) and NPC (182), emphasizing the more complex evolution of these tumors and their acquisition of multiple immune evasion strategies.